Table 5.

Research priorities related to COVID-19 vaccines in people with autoimmune rheumatic diseases.

Research PriorityRationale
Observational evidence on the frequency of harms (in particular serious AEs/serious disease flares) in people with ARDsIf very infrequent, may lower the importance of these outcomes
Evidence comparing the frequency of serious AEs and autoimmune AEs in people with ARDs to those without ARDsIf not different with sufficient certainty, the panel may decide not to rate the quality of evidence for harms down for indirectness
Evidence on the benefits (both clinical outcomes and serological studies) in people with ARDs on different medications, including the impact of off-label dosing on effectivenessMay help inform decisions regarding whether to hold medications around the time of vaccination and recommendations on optimal dosing intervals for 2-dose vaccines
Evidence on patient values preferences for the benefits and harms across different patient populationsWill help inform the relative importance of the outcomes
Understanding vaccine hesitancy and barriers to vaccine access faced by persons with ARDsWill help inform strategies to address vaccine hesitancy
Understanding vaccine benefits and harms in populations at risk for inequitiesWill help inform strategies to address inequity in vaccine access and uptake
  • AE: adverse event; ARD: autoimmune rheumatic disease; COVID-19: coronavirus disease 2019.